INTRODUCTION AND OBJECTIVES: In 2015, Prognostic
Grade Groups (PGG) 1 through 5 were introduced to reclassify Gleason pathology reporting. We studied the performance of the Prognostic Grade Groups (PGG) in the Shared Equal Access Regional Cancer Hospital (SEARCH) database for predicting perioperative oncologic outcomes within a multiracial equal access healthcare system. METHODS: We reviewed records of men who underwent radical prostatectomy at one of six Veterans Affairs hospitals between 1988 and 2015. 4,200 men with available data were included. The predictive utility of biopsy PGG for multiple perioperative clinical endpoints was examined using logistic regression models. Interactions between PGG and race were tested.
RESULTS: The cohort consisted of PGG 1 through 5, respectively: 1,989(47%), 1,142(27%), 515(12%), 402(10%), 152(4%). 1,569(38%) were African American(AA). Higher biopsy PGG was associated with higher stage, older age, higher preoperative PSA and more positive biopsy cores (p0.012). Higher PGG was associated with higher risk of extracapsular extension(ECE), seminal vesicle invasion(SVI), positive surgical margins(PSM) and lymph node involvement(LNI) and lower likelihood of achieving PSA nadir <0.01 after surgery (all p<0.001). Lower PGG was more likely to be upgraded at surgery (p¼<0.001). [ Table 1 . 197, No. 4S, Supplement, Friday, May 12, 2017 outcomes is currently unknown. Here, we investigated whether the proportion of the ductal component predicts oncologic outcomes in ductal adenocarcinoma. METHODS: We retrospectively reviewed clinical data from 3,038 patients with prostate cancer who underwent radical prostatectomy at our institution between 2005 and 2014. We excluded patients who received neoadjuvant or adjuvant treatment. Patients were stratified based on the proportion of the ductal component. We compared the probability of biochemical recurrence between groups and investigated how the proportion of the ductal component influences biochemical recurrence using Kaplan-Meier estimates and Cox regression models, respectively.
RESULTS: Of 2,648 patients, 101 (3.8%) had ductal adenocarcinoma and 2,547 (96.2%) had acinar adenocarcinoma. Biochemical recurrence-free survival for patients with ductal adenocarcinoma was significantly lower compared with those with acinar adenocarcinoma (p<0.001). When ductal cases were stratified by the proportion of the ductal component, biochemical recurrence-free survival for the high ductal component ( 30%) group was significantly lower compared that of the low ductal component (< 30%) group (p ¼ 0.023). In univariate and multivariate Cox regression analyses, a high ductal component was a significant predictor of biochemical recurrence (hazard ratio 2.508, 95% confidence interval 1.133-5.552, p ¼ 0.023).
CONCLUSIONS: The prognosis for ductal adenocarcinoma can be stratified by the proportion of the ductal component. This marker could potentially be used as a surrogate for poor prognosis or as a determinant for adjuvant therapy. METHODS: Data of patients with recurrent UC after primary treatment were collected in a retrospective multicenter (San Raffaele Hospital, Milan; IOVeIRCCS, Padua; Hospital of Ferrara, Ferrara; Mayo Clinic, Rochester; University of Bologna) study. Inclusion criteria were: 1) patients with a known history of UC in the bladder and/or in the upper urinary tract (UTUC); 2) FDG PET/CT images after curative treatment of the primary tumor; 3) morphological imaging modalities (CT and MRI) performed before at least 3 months from PET/CT and 4) available standard of reference (e.g. histological data or imaging modalities) for the assessment of PET/CT findings. Exclusion criteria were other abdominal tumours and chemotherapy administration concomitant to imaging and non-urothelial cancer variants. Sensitivities, specificities, positive and negative predictive values were evaluated for all patients and separately for bladder and UTUC. RESULTS: Overall, 287 patients were included in the study. Two-hundred thirteen patients underwent cystectomy (74.2%), 35 nephoureterectomy (12.2%), 32 both cystectomy and nephoureterectomy (11.1%) and 7 other type of treatment for UTUC (endo-urology or segmental ureterectomy). Neoadjuvant and adjuvant treatments were performed in 36 (12,5%) and 111 (38,7%) patients, respectively. Sensitivity and specificity of PET/CT for the detection of recurrent UC were 94% (91%-96%) and 79% (68%-88%), respectively (Table 1) . However, sensitivity was higher for bladder than UTUC cancer (95% vs. 85%) while specificity was lower in bladder cancer (78% vs. 85% for bladder and UTUC, respectively). The distribution of pathological FDG uptake was: 58 at local site, 126 at lymph nodes, 58 at skeletal site, 53 at lung, 28 at liver and 26 in other sites. PET/CT and morphological imaging modalities findings were available in 198 patients. The results were positively concordant in 137 patients, negatively concordant in 23 patients and discordant in 38 patients (20 negative at ceCT/MRI vs positive at PET/CT and 18 positive at ceCT/MRI and negative at PET/ CT) (K Cohen¼ 0.426; p<0.001). Sensitivities, specificities and accuracies of FDG PET/CT and morphological imaging for the detection of recurrent bladder and UTUC cancer were 94% (90%-97%) vs. 86% (81%-92%), 79% (67%-92%) vs. 59% (44%-74%) and 91% (87%-95%) vs. 81% (75%-86%), respectively. CONCLUSIONS: FDG PET/CT has a high diagnostic accuracy for the identification of recurrent UC, particularly in patients with bladder cancer. Moreover, its performance seems higher than conventional imaging for both bladder and UTUC cancer. Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e205
